Physician profile
Michael Springer
NPI 1689696445
$67,896.46
in general payments reported to CMS, 2019-2025
25 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $12.02 · 2021: $525 · 2022: $647 · 2023: $411 · 2024: $135 · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $66K · Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $66,000.00 |
| Food and Beverage | $546.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $66,000.00 | 2025 | |
| Abbvie INC. | $563.00 | 2020-2023 | Rinvoq, Skyrizi, Viberzi |
| Janssen Scientific Affairs, LLC | $241.12 | 2019-2021 | |
| Pfizer INC. | $172.82 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.29 | 2021-2024 | Gattex, Entyvio |
| Merck Sharp & Dohme LLC | $76.58 | 2019-2023 | Dificid |
| Amgen INC. | $75.08 | 2021-2023 | Amjevita, Avsola |
| Organon LLC | $70.19 | 2022-2024 | Renflexis, Hadlima |
| Qol Medical, LLC | $67.00 | 2021-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $66.62 | 2022 | |
| Genzyme Corporation | $59.47 | 2023-2024 | |
| Janssen Biotech, INC. | $51.12 | 2021-2023 | Simponi, Stelara, Remicade |
| Daiichi Sankyo INC. | $43.28 | 2022-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.12 | 2022-2023 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $34.54 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.96 | 2022-2023 | |
| Lilly USA, LLC | $24.47 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $23.50 | 2023 | Dupixent |
| Redhill Biopharma INC. | $23.07 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.32 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.36 | 2024 | Voquezna |
| Mirum Pharmaceuticals, INC. | $17.25 | 2023 | Livmarli |
| Aimmune Therapeutics, INC. | $17.08 | 2023 | |
| Celgene Corporation | $13.58 | 2023 | Zeposia |
| Boston Scientific Corporation | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.